Robert Mcwilliams - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Robert Mcwilliams's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Robert Mcwilliams
Verified
Broadcaster, Freelance
Danville, San Francisco
Beats
Entertainment, Iowa , Social Justice, Bands, Music , Waterloo, Cedar Falls , Race
Technology, finance, big business, sports
Content
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial - Nature Communications
By Jacob J. Orme, Robert McWilliams, Robert Mcwilliams Verified, Matthew Block, Aaron Mansfield, Svetomir N. Markovic, Haidong Dong, Fabrice Lucien, Jeffrey Winters Verified| Nature Verified AbstractImmune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial - Nature Communications
By Eric P Grewal, jun chen, Robert McWilliams, Robert Mcwilliams Verified, Lu Yang, Evidio Domingo-Musibay, Anastasios Dimou, Jane Hui, Vera J. Suman, Haidong Dong, Thomas J. Flotte| Nature Verified AbstractBoth targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses.
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial - Nature Communications
By Jacob J. Orme, Robert McWilliams, Robert Mcwilliams Verified, Matthew Block, Aaron Mansfield, Svetomir N. Markovic, Haidong Dong, Fabrice Lucien, Jeffrey Winters Verified| Nature Verified AbstractImmune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge.
Company Info
Freelance
Freelancer.com is the largest freelancing and crowdsourcing marketplace in the world, connecting over 81 million employers and freelancers across more than 247 countries. Founded in 2009 and based in Sydney, Australia, the platform allows employers to post jobs while freelancers can bid on these projects. It is publicly traded on the Australian Securities Exchange under the ticker ASX:FLN. The platform supports a variety of work categories, including software development, writing, design, and marketing. Freelancer.com also offers contests for creative work, where employers can award prize money to winning entries. Users can choose from different membership plans, including free and paid subscriptions, which provide various benefits. The mobile app enhances project management and communication for users on the go. With a diverse customer base that includes individuals, small businesses, and large enterprises, Freelancer.com plays a significant role in the global online economy.
De Pere, Wisconsin, United States